The short answer
Searches for peptides for menopause usually expect a product. The record points somewhere else: the peptide that matters most in menopause is one the body already makes, and the medicines that work on it block it rather than supply it.
- Neurokinin B, a brain peptide, drives hot flushes. Giving it to women causes them.
- The two FDA-approved non-hormonal treatments for hot flushes block its receptor. Neither is a peptide.
- The one peptide with a women's-health label, bremelanotide, is approved only before menopause.
The rest of this page sets out the evidence for each statement.
Where hot flushes come from
In the hypothalamus, beside the brain's temperature-control centre, sits a cluster of neurons named for the three signals they release: kisspeptin, neurokinin B and dynorphin — hence KNDy neurons. Oestrogen normally restrains them. As oestrogen falls in menopause they become more active, and expression of the gene encoding neurokinin B rises.
Neurokinin B acts on the NK3 receptor. The result, in the current model, is a false signal of overheating and the body's heat-loss response: flushing, sweating, a faster heart.
The model has unusually direct human support. In a randomised, double-blind, placebo-controlled crossover study, ten healthy women received a 30-minute intravenous infusion of neurokinin B and, separately, a vehicle infusion (Jayasena et al., Scientific Reports, 2015):
| Infusion | Women who flushed | Also measured |
|---|---|---|
| Neurokinin B | 8 of 10 | raised heart rate, raised skin temperature by probe and thermal imaging |
| Vehicle | 0 of 10 | — |
P = 0.0007. It is a small study, but it is the rare case in this library where a peptide's effect in people was tested blind against a control, and the answer was clear. The peptide causes the symptom.
The approved treatments block the peptide
Drug development went to the same receptor, and two medicines have now reached approval in the United States for moderate to severe vasomotor symptoms due to menopause:
| Medicine | What it blocks | Class | Label version |
|---|---|---|---|
| VEOZAH (fezolinetant, Astellas) | NK3 receptor — neurokinin B | small molecule | effective 2026-02-26 |
| LYNKUET (elinzanetant, Bayer) | NK1 and NK3 receptors — substance P and neurokinin B | small molecule | effective 2026-06-16 |
Both labels describe the same mechanism in their own words: blocking neurokinin signalling on the KNDy neurons to modulate activity in the thermoregulatory centre. Neither drug is a peptide, and neither is a hormone. They are in this library's hub because they are the answer to the question the search is really asking — what acts on the peptide biology of menopause — and because a page that listed only sold peptides would leave out the only approved options.
Bremelanotide: approved, but not after menopause
Bremelanotide is the melanocortin peptide sold as PT-141. It does have an FDA approval in women's health, as VYLEESI, for acquired, generalized hypoactive sexual desire disorder — and its label is specific about who:
indicated for the treatment of premenopausal women … VYLEESI is not indicated for the treatment of HSDD in postmenopausal women
Label effective 2025-11-13. So the one peptide with a women's-health label is approved for a population that excludes the one this page is about. Its label also states that the mechanism by which it improves desire is unknown.
Kisspeptin: in the circuit, not in a menopause trial
Kisspeptin is the K in KNDy, and that is why it appears in menopause searches. The research on giving it to people is real, but it concerns reproductive hormones and fertility — covered in the kisspeptin entry — not menopausal symptoms. A ClinicalTrials.gov search for kisspeptin and menopause on 2026-09-21 returned two records, and neither administers kisspeptin to a menopausal woman: one tests a herbal decoction and measures neuroendocrine markers, the other measures kisspeptin expression in cells around the egg during IVF.
A related idea was tested from the other side of the same circuit. Dynorphin, the D in KNDy, acts on kappa opioid receptors, and a small crossover pilot — twelve postmenopausal women randomised, eight analysed — tried a kappa agonist on hot flushes (Oakley et al., Menopause, 2015). It was a pilot, and it is not a peptide either.
What the record supports
- One peptide, neurokinin B, is established as a driver of hot flushes, including by a blinded human infusion study.
- Two approved medicines block its receptor; both are non-peptide small molecules.
- No peptide is approved for any menopausal symptom. The nearest, bremelanotide, is labelled for premenopausal women only.
- Kisspeptin has no registered menopause trial in the records checked.
Other questions that arrive through the same search belong to other pages. For skin changes, PeptideGlowJournal covers the cosmetic peptides; for weight and the GLP-1 drugs around menopause, GLP1Ledger has a dedicated page. In this library, the neighbouring hubs are peptides for sleep, which picks up the night-waking side of the picture, and the full list in the index of what peptides are used for.
Last checked
2026-09-21. Label indications and mechanisms for VEOZAH, LYNKUET and VYLEESI from the openFDA label endpoint; the neurokinin B infusion study (PMID 25683060) and the kappa-agonist pilot (PMID 25988798) read on PubMed; kisspeptin and menopause records from the ClinicalTrials.gov v2 API.